BHC Share Price Performance
US$5.75
5.75 (0.00%)
26.8% undervalued intrinsic discount
US$7.86
Fair Value
Price US$5.75
AnalystConsensusTarget US$7.86
AnalystLowTarget US$5.00
AnalystHighTarget US$10.00
Fair ValueUS$7.86
Share Pricen/a
Bausch Health Companies Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 23 Fair Values set on narratives written by author
BHC Community Narratives
AN
Fair Value
·Fair Value US$7.86 26.8% undervalued intrinsic discount
Gastroenterology Expansion And Global Markets Will Unlock Opportunities
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$5 15.0% overvalued intrinsic discount
Medicare Cuts, Heavy Debt And Global Competition Will Shrink Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$10 42.5% undervalued intrinsic discount
Aging Populations And Digital Health Will Revolutionize Patient Care
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Gastroenterology Expansion And Global Markets Will Unlock Opportunities
Key Takeaways Strategic acquisitions and late-stage drug development position the company to benefit from rising chronic disease rates and expanding healthcare access globally. Strong operating performance, ongoing deleveraging, and digital sales initiatives improve financial stability, operating margins, and long-term growth prospects.Read more
AN
US$7.86
26.8% undervalued intrinsic discount
Fair Value
Revenue
-1.96% p.a.
Profit Margin
3.74%
Future PE
11.33x
Price in 2029
US$10.98
Medicare Cuts, Heavy Debt And Global Competition Will Shrink Margins
Key Takeaways Forced drug price negotiations and broader pricing pressures threaten to sharply reduce profitability and compress margins across Bausch Health's existing portfolio. Heavy debt and limited R&D innovation increase risk of earnings decline, as generic competition and uncertain new product prospects undermine future revenue recovery.Read more
AN
US$5
15.0% overvalued intrinsic discount
Fair Value
Revenue
1.24% p.a.
Profit Margin
3.56%
Future PE
7.13x
Price in 2028
US$6.92
Aging Populations And Digital Health Will Revolutionize Patient Care
Key Takeaways Expansion in core therapeutics, global reach, and AI-driven platforms positions Bausch for strong recurring revenue and margin growth through new franchises and patient populations. Streamlining assets, resolving litigation, and aggressive debt reduction create operating leverage, lowering expenses and driving significant increases in earnings.Read more
AN
US$10
42.5% undervalued intrinsic discount
Fair Value
Revenue
2.99% p.a.
Profit Margin
3.39%
Future PE
14.22x
Price in 2028
US$13.83
Trending Discussion
Recently Updated Narratives
AN
BHC: Affordable Medicines Positioning Will Support Value Despite RED C And Separation Uncertainty
Fair Value: US$7.86 26.8% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Medicare Cuts, Heavy Debt And Global Competition Will Shrink Margins
Fair Value: US$5 15.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Digital Health Will Revolutionize Patient Care
Fair Value: US$10 42.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bausch Health Companies Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -3.23
- 71.04%
- -11.47%
- -1,919.0%
About BHC
- Founded
- n/a
- Employees
- 20300
- CEO
- WebsiteView website
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
